The NHS Galleri Trial Missed Its Primary Endpoint. Here is Why Oncologists Are Still Optimistic.

For decades, the holy grail of oncology has been a single, simple blood test capable of detecting cancer long before symptoms appear. In 2021, the UK’s National Health Service (NHS) partnered with California-based healthcare company GRAIL to launch the largest experiment of its kind: a trial involving 142,250 asymptomatic adults to test a multi-cancer early detection (MCED) tool known as Galleri.[4][5]

The premise was revolutionary. Instead of screening for individual cancers one by one—a logistical impossibility for the dozens of rare cancers that lack standard screening protocols—the Galleri test screens for more than 50 types of cancer simultaneously from a single blood draw.[1][3]

In late May 2026, the highly anticipated results of the three-year NHS-Galleri trial were finally presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. The data delivered a complex, highly debated verdict that immediately split the medical community.[1]

The headline finding was undeniably a setback: the trial missed its primary endpoint. The study was explicitly designed to prove that adding the Galleri test to standard care would significantly reduce the combined number of Stage III and Stage IV cancer diagnoses. Statistically, it failed to achieve that combined reduction, leading some anonymous delegates at the conference to bluntly declare that the trial had flopped.[1][2]

But in the world of population screening, a missed primary endpoint does not automatically render a technology useless. To understand why the trial's investigators remain deeply optimistic, it helps to look at how the Galleri test actually works at a molecular level.[3]

Tumors shed tiny fragments of genetic material into the bloodstream as their cells die, known as cell-free DNA (cfDNA). The Galleri test uses advanced sequencing technology to analyze these fragments, specifically looking for abnormal methylation patterns—chemical modifications that act like an on/off switch for genes and serve as a distinct signature of cancer.[2][3]

Because different tissues in the body have unique methylation profiles, the test does more than just sound an alarm; it predicts the signal of origin with over 90 percent accuracy. This tells doctors exactly where in the body to look, turning a vague warning into a targeted diagnostic roadmap.[3][5]

When researchers looked past the missed combined endpoint and isolated the data for Stage IV cancers—the most advanced and deadly form of the disease—a clear silver lining emerged. The trial demonstrated a greater than 20 percent reduction in Stage IV diagnoses among those who received the blood test.[4][5]

For oncologists, this distinction is massive. The gulf in survival rates and treatment options between a Stage III diagnosis and a metastatic Stage IV diagnosis is profound. Catching a tumor before it spreads throughout the body often means the difference between treating the cancer with curative intent and merely managing it palliatively.[4]

Furthermore, the trial revealed a 25 percent reduction in cancers diagnosed during emergency presentations, such as a patient rushing to the emergency room with sudden, severe symptoms. Emergency diagnoses historically carry the worst prognoses, making this reduction a highly meaningful clinical victory.[4][5]

The sheer volume of early detection also validated the test's core mechanism. Participants in the Galleri screening group saw a four-fold increase in screen-detected cancers compared to those receiving only standard-of-care screenings like mammograms and colonoscopies.[5]

Crucially, the test achieved this without triggering a wave of false alarms. A major fear with population-wide screening is that a high false-positive rate will subject thousands of healthy people to unnecessary anxiety, invasive biopsies, and crushing medical costs. The NHS trial confirmed a specificity of 99.55 percent, meaning the false-positive rate was just 0.45 percent.[3][5]

Despite these encouraging secondary metrics, independent experts urge caution. Critics argue that highlighting Stage IV reductions after missing the primary combined endpoint is a classic case of moving the goalposts. They stress that healthcare systems must rely on predefined metrics to ensure they are investing in tools that definitively alter population outcomes.[1]

NHS England appears to share this cautious approach. Following the ASCO presentation, the health service announced it will wait for further data and final analyses before deciding whether to fund a nationwide rollout of the Galleri test.[2]

Ultimately, the 2026 NHS-Galleri data represents a messy but monumental step forward. It proves that multi-cancer blood tests can work at a population scale, can accurately find tumors traditional screenings miss, and can intercept the deadliest cancers before they metastasize. The holy grail of oncology may not have arrived in perfect form, but it is undeniably closer than ever before.[3]